<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36705268</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Severe Fatigue and Persistent Symptoms at 3 Months Following Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study.</ArticleTitle><Pagination><StartPage>1930</StartPage><EndPage>1941</EndPage><MedlinePgn>1930-1941</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciad045</ELocationID><Abstract><AbstractText Label="BACKGROUND">Most research on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants focuses on initial symptomatology with limited longer-term data. We characterized prevalences of prolonged symptoms 3 months post-SARS-CoV-2 infection across 3 variant time-periods (pre-Delta, Delta, and Omicron).</AbstractText><AbstractText Label="METHODS">This multicenter prospective cohort study of adults with acute illness tested for SARS-CoV-2 compared fatigue severity, fatigue symptoms, organ system-based symptoms, and &#x2265;3 symptoms across variants among participants with a positive ("COVID-positive") or negative SARS-CoV-2 test ("COVID-negative") at 3 months after SARS-CoV-2 testing. Variant periods were defined by dates with &#x2265;50% dominant strain. We performed multivariable logistic regression modeling to estimate independent effects of variants adjusting for sociodemographics, baseline health, and vaccine status.</AbstractText><AbstractText Label="RESULTS">The study included 2402 COVID-positive and 821 COVID-negative participants. Among COVID-positives, 463 (19.3%) were pre-Delta, 1198 (49.9%) Delta, and 741 (30.8%) Omicron. The pre-Delta COVID-positive cohort exhibited more prolonged severe fatigue (16.7% vs 11.5% vs 12.3%; P = .017) and presence of &#x2265;3 prolonged symptoms (28.4% vs 21.7% vs 16.0%; P &lt; .001) compared with the Delta and Omicron cohorts. No differences were seen in the COVID-negatives across time-periods. In multivariable models adjusted for vaccination, severe fatigue and odds of having &#x2265;3 symptoms were no longer significant across variants.</AbstractText><AbstractText Label="CONCLUSIONS">Prolonged symptoms following SARS-CoV-2 infection were more common among participants infected during pre-Delta than with Delta and Omicron; however, these differences were no longer significant after adjusting for vaccination status, suggesting a beneficial effect of vaccination on risk of long-term symptoms. Clinical Trials Registration. NCT04610515.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gottlieb</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3276-8375</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ralph C</ForeName><Initials>RC</Initials><Identifier Source="ORCID">0000-0001-5382-9486</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Huihui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spatz</LastName><ForeName>Erica S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montoy</LastName><ForeName>Juan Carlos C</ForeName><Initials>JCC</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0000-0003-1354-1773</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of California - San Francisco School of Medicine, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Anna Marie</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmore</LastName><ForeName>Joann G</ForeName><Initials>JG</Initials><Identifier Source="ORCID">0000-0002-7311-6835</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannikainen</LastName><ForeName>Paavali A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Mandy</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, UTHealth Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huebinger</LastName><ForeName>Ryan M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, UTHealth Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idris</LastName><ForeName>Ahamed H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Zhenqiu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Informatics Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Laughlin</LastName><ForeName>Kelli N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Department of Global Health, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plumb</LastName><ForeName>Ian D</ForeName><Initials>ID</Initials><Identifier Source="ORCID">0000-0003-4747-381X</Identifier><AffiliationInfo><Affiliation>National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santangelo</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saydah</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willis</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Global Health, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wisk</LastName><ForeName>Lauren E</ForeName><Initials>LE</Initials><Identifier Source="ORCID">0000-0003-2932-4140</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatesh</LastName><ForeName>Arjun</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8248-0567</Identifier><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephens</LastName><ForeName>Kari A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinstein</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0002-3390-858X</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Cook County Hospital, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE) Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04610515</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Delta</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. M. G. reports the following institutional funding: Rush Center for Emerging Infectious Diseases Research Grant, Society for Academic Emergency Medicine Grant, Emergency Medicine Foundation/Council of Residency Directors in Emergency Medicine Education Research Grant, Emergency Medicine: Reviews and Perspectives Medical Education Research Grant, and University of Ottawa Department of Medicine Education Grant. E. S. S. receives grant funding from the National Institute on Minority Health and Health Disparities (U54MD010711-01), the US Food and Drug Administration (FDA) to support projects within the Yale&#x2013;Mayo Clinic Center of Excellence in Regulatory Science and Innovation (U01FD005938), the National Institute of Biomedical Imaging and Bioengineering (R01 EB028106-01), and the National Heart, Lung, and Blood Institute (R01HL151240); and has received honorarium paid to author for a 1-day educational session from Regeneron. J. G. E. reports serving as Editor in Chief of Adult Primary Care topics for UpToDate. A. V. reports funding for coronavirus disease 2019 (COVID-19)&#x2013;related studies from the Society of Academic Emergency Medicine Foundation Emerging Infectious Disease and Preparedness Grant, the Agency for Healthcare Research and Quality (R01 HS 28340-01), the FDA (ID: 75F40120C00174), and the Emergency Medicine Health Policy Institute/Emergency Medicine Foundation; grants or contracts from the American Board of Emergency Medicine National Academy of Medicine Fellowship, Centers for Medicare and Medicaid Services, National Institute on Drug Abuse, Moore Foundation, Genentech, and FORE Foundation; consulting fees from Liminal Sciences; payment for expert testimony from Salvi, Shostok &amp; Pritchard; support for attending meetings and/or travel from the American College of Emergency Physician, and stock or stock options with Hyperfine Inc/Liminal Sciences. A. H. I. reports participation on a data and safety monitoring board (DSMB) or advisory board for Stryker, Inc. A. M. C. reports grants or contracts from the CDC, unrelated to this work. L. E. W. reports participation on a DSMB or advisory board for a diabetes project at University of Washington. R. R. reports a grant from the National Institute of Allergy and Infectious Diseases (R01 AI166967-01, all payments made to the University of California, San Francisco). R. A. W. reports consulting fees from UpToDate as a reviewer for infection control sections, and participation as unpaid member of a scientific advisory board for the European Clinical Research Alliance on Infectious Diseases Foundation. S. M. reports an NIH Institutional Training Grant (5KL2TR003981-02), not related to the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Weinstein</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gottlieb</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santangelo</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koo</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Derden</LastName><ForeName>Antonia</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gottlieb</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gatling</LastName><ForeName>Kristyn</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guzman</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaadan</LastName><ForeName>Marshall</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassaballa</LastName><ForeName>Minna</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jerger</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Zohaib</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choi</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Venkatesh</LastName><ForeName>Arjun</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spatz</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Zhenqiu</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Shu-Xia</ForeName><Initials>SX</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Huihui</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mannan</LastName><ForeName>Imtiaz Ebna</ForeName><Initials>IE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>Zimo</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Venkatesh</LastName><ForeName>Arjun</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spatz</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kinsman</LastName><ForeName>Jeremiah</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dorney</LastName><ForeName>Jocelyn</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pierce</LastName><ForeName>Senyte</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Puente</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nichol</LastName><ForeName>Graham</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephens</LastName><ForeName>Kari</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morse</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maat</LastName><ForeName>Zenoura</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stober</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Laughlin</LastName><ForeName>Kelli N</ForeName><Initials>KN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gentile</LastName><ForeName>Nikki</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geyer</LastName><ForeName>Rachel E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willis</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malone</LastName><ForeName>Kerry</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>Jasmine</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rising</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kean</LastName><ForeName>Efrat</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelly</LastName><ForeName>Morgan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaeffer</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hannikainen</LastName><ForeName>Paavali</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shughart</LastName><ForeName>Lindsey</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shughart</LastName><ForeName>Hailey</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Renzi</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amadio</LastName><ForeName>Grace</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grau</LastName><ForeName>Dylan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watts</LastName><ForeName>Phillip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheng</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miao</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shutty</LastName><ForeName>Carly</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charlton</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hill</LastName><ForeName>Mandy</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Site</LastName><ForeName>Ryan Huebinger</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chavez</LastName><ForeName>Summer</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kane</LastName><ForeName>Arun</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nikonowicz</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Idris</LastName><ForeName>Ahamed H</ForeName><Initials>AH</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDonald</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallegos</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Riley</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elmore</LastName><ForeName>Joann G</ForeName><Initials>JG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wisk</LastName><ForeName>Lauren E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>L'Hommedieu</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chandler</LastName><ForeName>Christopher W</ForeName><Initials>CW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eguchi</LastName><ForeName>Megan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roldan</LastName><ForeName>Kate Diaz</ForeName><Initials>KD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moreno</LastName><ForeName>Raul</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Ralph C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montoy</LastName><ForeName>Juan Carlos C</ForeName><Initials>JCC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kemball</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chavez</LastName><ForeName>Cecilia Lara</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arreguin</LastName><ForeName>Mireya</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plumb</LastName><ForeName>Ian D</ForeName><Initials>ID</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Aron J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saydah</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Briggs-Hagen</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>27</Day><Hour>7</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36705268</ArticleId><ArticleId IdType="pmc">PMC10249989</ArticleId><ArticleId IdType="doi">10.1093/cid/ciad045</ArticleId><ArticleId IdType="pii">7007177</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Centers for Disease Control and Prevention . SARS-CoV-2 variant classifications and definitions. Available at:https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html#concern. Accessed 28 August 2022.</Citation></Reference><Reference><Citation>Taylor CA, Patel K, Pham H, et al. . Severity of disease among adults hospitalized with laboratory-confirmed COVID-19 before and during the period of SARS-CoV-2 B.1.617.2 (Delta) predominance&#x2014;COVID-NET, 14 states, January&#x2013;August 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1513&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553023</ArticleId><ArticleId IdType="pubmed">34710076</ArticleId></ArticleIdList></Reference><Reference><Citation>Iuliano AD, Brunkard JM, Boehmer TK, et al. . Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods&#x2014;United States, December 2020&#x2013;January 2022. MMWR Morb Mortal Wkly Rep 2022; 71:146&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9351529</ArticleId><ArticleId IdType="pubmed">35085225</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg T, Twohig KA, Harris RJ, et al. . Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. BMJ 2021; 373:n1412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8204098</ArticleId><ArticleId IdType="pubmed">34130987</ArticleId></ArticleIdList></Reference><Reference><Citation>Houhamdi L, Gautret P, Hoang VT, Fournier P-E, Colson P, Raoult D. Characteristics of the first 1119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November&#x2013;December 2021. J Med Virol 2022; 94:2290&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015264</ArticleId><ArticleId IdType="pubmed">35060146</ArticleId></ArticleIdList></Reference><Reference><Citation>Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves. JAMA 2022; 327:583&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8719272</ArticleId><ArticleId IdType="pubmed">34967859</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. . Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 2021; 4:e2128568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Romieu AC, Leung S, Mbanya A, et al. . Health care utilization and clinical characteristics of nonhospitalized adults in an integrated health care system 28&#x2013;180 days after COVID-19 diagnosis&#x2014;Georgia, May 2020&#x2013;March 2021. MMWR Morb Mortal Wkly Rep 2021; 70:644&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084119</ArticleId><ArticleId IdType="pubmed">33914727</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschtick JL, Titus AR, Slocum E, et al. . Population-based estimates of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) prevalence and characteristics. Clin Infect Dis 2021; 73:2055&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8240848</ArticleId><ArticleId IdType="pubmed">34007978</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, et al. . Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open 2021; 4:e210830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisk LE, Gottlieb M, Spatz ES, et al. . Association of initial SARS-CoV-2 test positivity with patient-reported well-being 3 months after a symptomatic illness. JAMA Netw Open 2022; 5:e2244486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9716377</ArticleId><ArticleId IdType="pubmed">36454572</ArticleId></ArticleIdList></Reference><Reference><Citation>Spatz ES, Gottlieb M, Wisk LE, et al. . Three-month symptom profiles among symptomatic adults with positive and negative severe acute respiratory syndrome coronavirus 2 tests: a prospective cohort study from the INSPIRE group. Clin Infect Dis 2023; 76:1559&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11361781</ArticleId><ArticleId IdType="pubmed">36573005</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AK, Wang X, McCluskey LP, et al. . Neuropsychiatric sequelae of long COVID-19: pilot results from the COVID-19 neurological and molecular prospective cohort study in Georgia, USA. Brain Behav Immun Health 2022; 24:100491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9290328</ArticleId><ArticleId IdType="pubmed">35873350</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Laughlin KN, Thompson M, Hota B, et al. . Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): a longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection. PLoS One 2022; 17:e0264260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893622</ArticleId><ArticleId IdType="pubmed">35239680</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler CX, Wyller VBB, Moss-Morris R, et al. . Long COVID and post-infective fatigue syndrome: a review. Open Forum Infect Dis 2021; 8:ofab440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8496765</ArticleId><ArticleId IdType="pubmed">34631916</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner D, Nisenbaum R, Heim C, Jones JF, Unger ER, Reeves WC. Psychometric properties of the CDC symptom inventory for assessment of chronic fatigue syndrome. Popul Health Metr 2005; 3:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1183246</ArticleId><ArticleId IdType="pubmed">16042777</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves WC, Wagner D, Nisenbaum R, et al. . Chronic fatigue syndrome&#x2014;a clinically empirical approach to its definition and study. BMC Med 2005; 3:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1334212</ArticleId><ArticleId IdType="pubmed">16356178</ArticleId></ArticleIdList></Reference><Reference><Citation>Spudich S, Nath A. Nervous system consequences of COVID-19. Science 2022; 375:267&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">35050660</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor CA, Whitaker M, Anglin O, et al. . COVID-19-associated hospitalizations among adults during SARS-CoV-2 Delta and Omicron variant predominance, by race/ethnicity and vaccination status&#x2014;COVID-NET, 14 states, July 2021&#x2013;January 2022. MMWR Morb Mortal Wkly Rep 2022; 71:466&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8956338</ArticleId><ArticleId IdType="pubmed">35324880</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention . COVID data tracker. Available at:https://covid.cdc.gov/covid-data-tracker/#variant-proportions. Accessed 28 August 2022.</Citation></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, et al. . Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One 2020; 15:e0240784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open 2021; 4:e2111417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Valko PO, Bassetti CL, Bloch KE, Held U, Baumann CR. Validation of the fatigue severity scale in a Swiss cohort. Sleep 2008; 31:1601&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2579971</ArticleId><ArticleId IdType="pubmed">19014080</ArticleId></ArticleIdList></Reference><Reference><Citation>Vihta KD, Pouwels KB, Peto TE, et al. . Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. Clin Infect Dis 2022; 76:e133&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384604</ArticleId><ArticleId IdType="pubmed">35917440</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. . Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med 2022; 28:1706&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, et al. . Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ 2022; 377:e069676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, Braillard O, Salamun J, et al. . Symptoms after COVID-19 vaccination in patients with post-acute sequelae of SARS-CoV-2. J Gen Intern Med 2022; 37:1585&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863092</ArticleId><ArticleId IdType="pubmed">35194744</ArticleId></ArticleIdList></Reference><Reference><Citation>
Tran V-T, Perrodeau E, Saldanha J, Pane I, Ravaud P. 
Efficacy of COVID-19 vaccination on the symptoms of patients with long COVID: a target trial emulation using data from the ComPaRe e-cohort in France.
Res Square [Preprint].
February 17, 2022 [cited 2022 Aug 28]. Available from:
https://www.researchsquare.com/article/rs-1350429/v1.</Citation></Reference><Reference><Citation>
Senjam SS, Balhara YPS, Kumar P, et al. . 
Assessment of post COVID-19 health problems and its determinants in North India: a descriptive cross section study.
medRxiv [Preprint]
. October 7, 2021 [cited 2022 Aug 28]. Available from:
http://medrxiv.org/lookup/doi/10.1101/2021.10.03.21264490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.03.21264490</ArticleId></ArticleIdList></Reference><Reference><Citation>Zisis SN, Durieux JC, Mouchati C, Perez JA, McComsey GA. The protective effect of coronavirus disease 2019 (COVID-19) vaccination on postacute sequelae of COVID-19: a multicenter study from a large national health research network. Open Forum Infect Dis 2022; 9:ofac228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9129153</ArticleId><ArticleId IdType="pubmed">35818362</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E, Levi R, Sarti R, et al. . Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA 2022; 328:676&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med 2022; 28:1461&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Polidori L, et al. . Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of Omicron and Delta variant dominance: a prospective observational study from the ZOE COVID study. Lancet 2022; 399:1618&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with Delta versus Omicron variants of SARS-CoV-2. Lancet 2022; 399:2263&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>